Purvalanol A
Chemical Name: (2R)-2-[[6-[(3-Chlorophenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-1-butanol
Purity: ≥98%
Biological Activity
Purvalanol A is a cyclin-dependent kinase (cdk) inhibitor (reported IC50 values are 4, 4 - 70, 75 - 240 and 100 nM for cdk1, cdk2, cdk5 and cdk 7, respectively). Reversibly arrests synchronised cells in G1 and G2, and inhibits cell proliferation and cell death.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Additional Information
Background References
-
The specificities of protein kinase inhibitors: an update.
Bain et al.
Biochem.J., 2003;371:199 -
How selective are pharmacological inhibitors of cell-cycle-regulating cyclin-dependent kinases?
Jorda et al.
J.Med.Chem., 2018;61:9105 -
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.
Gray et al.
Science, 1998;281:533 -
ATP-site directed inhibitors of cyclin-dependent kinases.
Gray et al.
Curr.Med.Chem., 1999;6:859 -
Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities.
Villerbu et al.
Int.J.Cancer, 2002;97:761
Product Datasheets
Reconstitution Calculator
Molarity Calculator
Citations for Purvalanol A
The citations listed below are publications that use Tocris products. Selected citations for Purvalanol A include:
8 Citations: Showing 1 - 8
-
Comparative phosphoproteomic analysis reveals signaling networks regulating monopolar and bipolar cytokinesis.
Authors: Karayel Et al.
Sci Rep 2018;8:2269
-
CDK-1 Inhibition in G2 Stabilizes Kinetochore-Microtubules in the following Mitosis.
Authors: Gayek and Ohi
PLoS One 2016;11:e0157491
-
Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells.
Authors: Origanti Et al.
Oncogene 2013;32:577
-
NuMA localization, stability, and function in spindle orientation involve 4.1 and Cdk1 interactions.
Authors: Seldin Et al.
Mol Biol Cell 2013;24:3651
-
Initial diameter of the polar body contractile ring is minimized by the centralspindlin complex.
Authors: Fabritius Et al.
Dev Biol 2011;359:137
-
Binding partner switching on microtubules and aurora-B in the mitosis to cytokinesis transition.
Authors: Ozlü Et al.
Mol Cell Proteomics 2010;9:336
-
Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice.
Authors: Rowe Et al.
Antiviral Res 2010;86:276
-
Potentiation of PacT.-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.
Authors: Pennati Et al.
Mol Cancer Ther 2005;4:1328
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for Purvalanol A
There are currently no reviews for this product. Be the first to review Purvalanol A and earn rewards!
Have you used Purvalanol A?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
